Confined or spread disease-Spread beyond the prostate gland Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread beyond the prostate gland Posts on Medivizor

Searching for patients with advanced prostate cancer to trial an immunotherapy

Searching for patients with advanced prostate cancer to trial an immunotherapy

Posted by on Apr 30, 2021 in Prostate cancer | 0 comments

In a nutshell This trial is aiming to assess the effectiveness of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in treating metastatic prostate cancer according to the percentage of CD8 cells patients have. The main outcomes that are to be measured are the clinical benefit rate and the percentage of CD8 cells on biopsy during...

Read More

Which hormonal therapy should be first in patients with castration-resistant metastatic prostate cancer?

Which hormonal therapy should be first in patients with castration-resistant metastatic prostate cancer?

Posted by on Apr 18, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed and evaluated which hormonal therapy should be given first, abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) or enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that AAP followed by ENZ is more effective in delaying...

Read More

Evaluating the effectiveness of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread

Evaluating the effectiveness of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread

Posted by on Jan 17, 2021 in Prostate cancer | 0 comments

In a nutshell This study examined the impact of the pattern of metastatic spread on the effectiveness of enzalutamide in combination with androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that the combination has good outcomes in men with bone and/or lymph node...

Read More

Evaluating combination therapies for metastatic hormone-sensitive prostate cancer.

Evaluating combination therapies for metastatic hormone-sensitive prostate cancer.

Posted by on Jan 17, 2021 in Prostate cancer | 0 comments

In a nutshell This study was carried out to look at the use of combining radiotherapy (RT), systemic therapy (ST; whole-body treatment), and androgen deprivation therapy (ADT) for prostate cancer (PC) that is hormone-sensitive and has spread. The authors concluded that ADT plus RT led to better outcomes in patients with low-volume disease. Some...

Read More

Seeking men with metastatic castration-resistant prostate cancer to trial a combination therapy

Seeking men with metastatic castration-resistant prostate cancer to trial a combination therapy

Posted by on Dec 15, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is evaluating the effectiveness and safety of combining nivolumab (Opdivo) with docetaxel (Taxotere) and prednisone (Deltasone) in men with metastatic castration-resistant prostate cancer (mCRPC). The main outcomes to be evaluated will be survival without cancer worsening and overall survival. The details CRPC is a difficult...

Read More

Evaluating the impact on quality of life of giving enzulatumide in combination with hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

Evaluating the impact on quality of life of giving enzulatumide in combination with hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

Posted by on Dec 6, 2020 in Prostate cancer | 0 comments

In a nutshell This study investigated the quality of life after treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) with enzalutamide (Xtandi) in combination with hormone therapy. The study found that enzalutamide + hormone therapy improved the quality of life of patients, compared to hormone therapy...

Read More

Does giving radiotherapy to metastatic sites and the prostate tumor improve the outcomes of patients with prostate cancer and few metastases?

Does giving radiotherapy to metastatic sites and the prostate tumor improve the outcomes of patients with prostate cancer and few metastases?

Posted by on Nov 25, 2020 in Prostate cancer | 0 comments

In a nutshell This study aims to evaluate if giving radiotherapy to both the areas the tumor has spread (metastases), along with the prostate tumor, will improve the survival of patients with prostate cancer (PC) and few metastases (oligometastatic disease). This study suggested that this treatment could benefit patients with PC and few...

Read More

Ipilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer

Ipilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer

Posted by on Sep 30, 2020 in Prostate cancer | 0 comments

In a nutshell This trial was carried out to examine the effectiveness of radiotherapy followed by treatment with ipilimumab (Yervoy) in men with metastatic castrate-resistant prostate cancer  (mCRPC). The trial found that this treatment led to higher survival in these patients compared to radiotherapy followed by placebo. Some...

Read More

The effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer

The effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer

Posted by on Jul 19, 2020 in Prostate cancer | 0 comments

In a nutshell The study evaluated outcomes of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) who were continuing drugs targeting androgen receptors (AR). The authors found that BAT was clinically effective in such patients. Some background BAT refers to sequential injections with testosterone in men...

Read More

The use of relugolix in addition to radiotherapy in patients with prostate cancer

Posted by on May 2, 2020 in Prostate cancer | 0 comments

In a nutshell The study investigated the use of relugolix (Relumina), a hormonal therapy drug, in addition to radiotherapy (RT), in managing prostate cancer. The study found that relugolix was effective in reducing androgen (male sex hormones such as testosterone) levels and well tolerated in these patients. Some background Prostate...

Read More

Evaluating docetaxel plus hormone therapy for the treatment of metastatic prostate cancer

Posted by on Nov 3, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of docetaxel (Taxotere) plus hormone therapy for patients with metastatic prostate cancer (cancer that spread outside the prostate). This study found that this treatment combination improved survival for these patients, regardless of tumor burden. Some background One treatment for...

Read More

Evaluating the overall survival in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Posted by on Oct 27, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated the effect of apalutamide (Erleada) on survival in patients with castrate-resistant prostate cancer (CRPC). This study found that apalutamide had a positive effect on the survival of these patients. Some background One treatment option for patients with prostate cancer is androgen deprivation therapy...

Read More